Drugs / NCO-48
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04309526 | Mar → Aug 2020 | hepatitis B virus infection | Nucorion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCO-48 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04309526 ↗ |
| Known as | NCO-48 Fumarate | “NCO-48 Fumarate will be assessed in healthy subjects (6 groups of 8 subjects each).” NCT04309526 ↗ |
| Route | Oral | “single oral dose” NCT04309526 ↗ |